Telemedicine Monitoring for Depression After Hospital Stay
Tests telemedicine follow-up added to usual care in adults with major depression after hospital stay.
Key facts
- Who runs it
- Assistance Publique - Hôpitaux de Paris
- Where
- Paris, FranceSee the site
- Trial code
- Registry title
- Relevance of a Telemedicine Monitoring in the Management of Depression
- Status
- Recruiting
- People taking part
- 836 people, planned
- Started
- 27 May 2024
- Expected to end
- 2 Feb 2029
- Type of study
- Interventional, 2 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- Telemedicine session
- Record updated
- 22 August 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a depressive episode who were in hospital for a medical or surgical reason and started or changed a psychotropic medicine there. It tests telemedicine follow-up added to usual care.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- A depressive episode meeting DSM5 criteria, seen by a liaison psychiatrist during a hospital stay in medicine or surgery. The episode must be mild enough for care outside hospital.
- Earlier treatment
- A psychotropic medicine (antidepressant or anxiolytic) was started, changed or adjusted by the liaison psychiatrist during the hospital stay.
Main reasons for not taking part
- Pregnant women
- Hospital stay for psychiatric reasons, such as a suicide attempt
- High suicide risk at the screening visit
- Mood disorder other than depression, or other psychiatric conditions such as addictions or delusional disorders
- No internet access or other problems that make telemedicine impossible
The registry criteria, word for word
Show all 19 criteriaShow less
Who can take part
- Age ≥ 18 years
- Presence of DSM5 criteria for the diagnosis of a characterized depressive episode
- Patient hospitalized in MCO with request for liaison psychiatry opinion whatever the hospitalization modality (full hospitalization, weekday hospitalization or day hospitalization)
- Initiation, change of molecule or modification of a psychotropic treatment (antidepressant or anxiolytic) during MCO hospitalization by the liaison psychiatrist
- Affiliated or entitled to a social security system (except AME)
- Obtaining free, written and informed consent
Who cannot take part
- Patient is part of a psychiatric care program at the time of the selection visit
- Presence of a mood disorder other than CDD
- Reason for MCO hospitalization secondary to psychiatric disorders, in particular suicide attempts
- Psychiatric comorbidities assessed by psychiatrist, in particular addictions (excluding tobacco), delusional disorders, post-traumatic stress disorder, anxiety disorders (excluding GAD)
- Presence of a non-psychiatric condition with a vital prognosis of less than 3 years
- Conditions making consent impossible (major cognitive disorders, etc.)
- Severity of the depressive episode incompatible with outpatient care and relevant to an indication for hospitalization in psychiatry
- MCO hospitalization prolonged beyond 3 weeks after initiation, change of molecule or modification of psychotropic treatment dosage
- High suicidal risk at the screening visit assessed by psychiatrist
- Contraindications to telemedicine (no internet access, major vision problems, major cognitive problems, marked impulsivity, clinical situation requiring information to be communicated in person, etc.)
- Deprived of liberty or under a protective measure (guardianship or under curatorship)
- Pregnant woman
- Refusal of the patient
Where in France
- Hopital Pitie-SalpetriereParis, FranceContact: Jean Yves ROTGE, PrTaking people
About the trial
What the trial wants to find out
Major depressive disorder (MDD) is a common chronic disease. It is the main cause of morbidity and disability in the world with, among other things, an increase in cardio-metabolic risk and a reduction in life expectancy, regardless of suicide risk. MDD is the most expensive medical condition: 10-20 billion €/year in France. This cost is mainly attributable to the functional consequences of the disease, highlighting the medico-economic challenge represented by the optimization of the organization of care.
Read full original descriptionShow less
In France, more than 80% of MDD patients are enrolled in non-psychiatric care pathways, mainly primary care or MSO hospital care (medicine, surgery, obstetrics). Unfortunately, less than half of patients benefit from treatment at an appropriate dosage or duration, thus exposing them to the risks of relapse, recurrence and chronic evolution. It is necessary to optimize this management, in particular by improving secondary prevention, which consists of maintaining treatment in the months following symptomatic remission.
Several support programs (monitoring with assessment of symptomatology) have shown their effectiveness on depressive symptomatology with a favorable medico-economic report, in particular by allowing maintenance of antidepressant treatment. None of these studies have been conducted on French care pathways.
Investigators propose to evaluate the efficacy of telemedicine management (added to usual care) in non-psychiatric care pathways on the evolution of depressive symptomatology for MDD patients. Investigators hypothesize that telemedicine monitoring downstream of MSO hospitalization will increase the response rate to antidepressants at 6 months and reduce the costs attributed to depressive symptoms compared to usual care, in particular by optimizing secondary prevention strategies by maintaining treatment.
The main objective of the research is to assess the efficacy of telemedicine monitoring on depressive symptoms and treatments, added to the out-of-hospital downstream care pathways for patients initially hospitalized in MSO (medicine-surgery-obstetrics), compared to usual care.
The 2 groups in the trial
- Standard armNo study treatment, for comparison
Patients will have the usual care
- Interventional armTreatment being tested
Patients will have telemedicine session
Treatment: Telemedicine session
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Randomized Multicenter Clinical Trial of the Efficacy of a Telemedicine Monitoring in the Management of a Depressive Episode After an Hospitalisation in Medicine or Surgery
- Plain-language title
- Telemedicine Monitoring for Depression After Hospital StayGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 22 August 2025